The Food and Drug Administration approved daraxonrasib — sold as Rasonque by Revolution Medicines — on 26 August 2026 for adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic therapy, or who cannot take multiagent chemotherapy. The agency called it a first-in-class RAS inhibitor for the most common form of the disease, and said the nod came months ahead of the original timetable.

The New York Times described a disease long treated as one of the most hopeless in medicine. The label is not a cure. It is a targeted tablet for people who have already been through chemo. That is still a different sentence than “nothing works.”

What the label actually says

Indication: metastatic pancreatic adenocarcinoma, prior systemic therapy or unfit for multiagent regimens. Sponsor: Revolution Medicines. Mechanism: RAS(ON) inhibition — the company calls it the first broad RAS-targeted medicine in this setting. Those are the sponsor’s words, filed in a 26 August release. Survival curves belong in the trial, not in a press kit.

The science is real enough for the FDA to sign. The price will be set by a company that answers to a ticker. Hold both facts in the same hand.